Seeking Alpha
16 Nov 2026, 12:42 UTC · 12h ago
BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Impact · against what's priced in
BridgeBio faces a critical execution phase with three product launches slated for the next seven months, including an imminent LGMD2I launch. While Attruby's $1 billion growth provides a foundation, the concentration of upcoming PDUFA dates for achondroplasia and ADH1 introduces significant operational risk.
- BBIO+0.30
No priced-in read yet





